# Lemborexant (Dayvigo)

Source: https://ourhealthnetwork.com/drugs/lemborexant
Data: FDA Orange Book and OpenFDA, refreshed periodically

## What is Lemborexant?

Lemborexant (brand name: Dayvigo) is an orexin receptor antagonist. It is prescribed to treat sleep initiation and maintenance disorders. Across the United States, 1,000 doctors prescribe Lemborexant to approximately 582 Medicare patients.

## Brand names

Dayvigo

## Indications

Lemborexant is primarily prescribed for the treatment of sleep initiation and maintenance disorders.

## Conditions treated

- [Sleep Initiation and Maintenance Disorders](https://ourhealthnetwork.com/conditions/sleep-initiation-and-maintenance-disorders)

## Mechanism of action

The mechanism of action of lemborexant in the treatment of insomnia is presumed to be through antagonism of orexin receptors. The orexin neuropeptide signaling system plays a role in wakefulness.

## Drug classification

- Established Pharmacologic Class: Orexin Receptor Antagonist [EPC]
- Mechanism of Action class: Orexin Receptor Antagonists [MoA]
- Route of administration: ORAL

## Common side effects

adverse reaction (reported in ≥5% of patients treated with DAYVIGO and at least twice the rate of placebo) was somnolence

## Sources and disclaimers

- FDA Orange Book and OpenFDA dataset
- This information is for educational purposes only and does not constitute medical advice. Always consult a healthcare professional before starting, stopping, or changing any medication.

## Related

- [All drugs](https://ourhealthnetwork.com/drugs)
- [Find specialists who prescribe this drug](https://ourhealthnetwork.com/find-doctors)
- [Methodology](https://ourhealthnetwork.com/methodology)